GlassScriptPhysician profile
Nelson Emmanuel Cordero-Torres
NPI 1033351184
$1,995.06
in general payments reported to CMS, 2019-2025
21 companies · $69.94 in 2025
The $69.94 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $336 · 2021: $504 · 2022: $121 · 2023: $151 · 2024: $217 · 2025: $69.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $380.95 | 2019-2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $369.14 | 2019-2021 | |
| Allergan, INC. | $312.47 | 2019-2020 | |
| Abbvie INC. | $266.53 | 2021-2023 | Vraylar |
| Axsome Therapeutics, INC. | $124.99 | 2024 | Auvelity |
| Aurinia Pharma U.S., INC. | $77.73 | 2022 | |
| Neurocrine Biosciences, INC. | $65.74 | 2020-2023 | Ingrezza |
| Indivior INC. | $62.01 | 2019-2024 | Perseris |
| Livanova USA, INC. | $39.28 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Alkermes, INC. | $38.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.04 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $30.89 | 2019-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $27.31 | 2025 | Cobenfy |
| Orexo US, INC. | $24.89 | 2021 | |
| Janssen Scientific Affairs, LLC | $24.77 | 2025 | Invega Sustenna, Invega Trinza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.31 | 2023 | |
| Sunovion Pharmaceuticals INC. | $22.26 | 2021 | |
| Merck Sharp & Dohme LLC | $20.52 | 2020 | |
| Vanda Pharmaceuticals INC. | $18.88 | 2021 | |
| Adlon Therapeutics L.P. | $16.96 | 2020 | |
| Neos Therapeutics, LP | $13.51 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Cordero-Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.